IDO1 and acute myeloid leukemia: Indeed, hierarchal clustering of gene expression data from AML bone marrow samples of patients receiving CD3/CD123 bispecific antibody flotetuzumab demonstrated higher immune scores for a number of MSC-associated modulatory signatures such as IDO1, TGFβ, and PDL2, as well a stromal biological signature, in non- and partial responders in comparison with complete responders [34].